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DOI: 10.1039/c1fo10112aIt is essential to guarantee the safety of unprocessed plants and food supplements if consumers’ health is
to be protected. Although botanicals and their preparations are regulated at EU level, at least in part,
there is still considerable discretion at national level, and Member States may choose to classify
a product either as a food supplement or as a drug. Accurate data concerning the finished products and
the plant used as the starting point are of major importance if risks and safety are to be properly
assessed, but in addition standardized criteria for herbal preparation must be laid down and respected
by researchers and manufacturers. Physiologically active as well as potentially toxic constituents need
to be identified, and suitable analytical methods for their measurement specified, particularly in view of
the increasing incidence of economically motivated adulteration of herbal raw materials and extracts. It
remains the duty of food operators to keep up with the scientific literature and to provide sufficient
information to enable the adaptation of specifications, sampling schemes and analytical methods to
a fast-changing environment.1 Introduction
In the European Community the main regulations that are
relevant in this field are Directive 2002/46/EC1 on food supple-
ments and Directive 2004/24/EC2 on traditional herbal medicinal
products for human use.
At present, botanicals and botanical preparations are partially
harmonised at EU level (among others: Directive 2002/46/EC1
and EC Regulations 396/2005/EC,3 1881/2006/EC,4 and 1925/
2006/EC5), but there is still considerable discretion at national
level.
For the consumer, quality of a product means suitability for
use, reliability, efficacy, and above all its safety. Elements that
may affect the safety of plant food supplements (PFS) are:
– the presence of toxic compounds;
– the presence of pharmacologically active substances;
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740 | Food Funct., 2011, 2, 740–746– adverse reactions to, and drug interactions with, otherwise
non toxic substances;
– genetic variants among the plant species;
– differences in processing and manufacturing conditions.
Some other problems are addressed in this section:
– misidentification of the initial plant source;
– adulteration with other plants;
– environmental contamination (e.g., with heavy metals and
pesticide or herbicide residues);
– biological contamination (mycotoxins, micro-organisms);
– the addition of illegal substances.2 General safety considerations
Labelling of a herbal supplement as ‘‘natural’’ does not mean it is
guaranteed not to have harmful effects. For example, the herbs
kava (Piper methysticum) and comfrey (Symphytum officinale)
have been linked to serious liver damage.6,7
Data about the finished products and the quality of the
botanical used for PFS are of major importance for risk assess-
ment and safety evaluation. As not all the active ingredient(s) in
herbal supplements have to be identified, it is important for
researchers and manufacturers to have and to respect standard-
ization criteria for PFS preparations. An important approach is
to specify the constituents, which can be used as markers for
monitoring quality. They must be measured using defined
analytical methods.8 Even if a marker is not linked to bioactivity
or a therapeutic effect, it can function as an index of product
consistency and quality control.9
A large number of chemical compounds in the plant may be
needed to provide the desired physiological effect in humans,This journal is ª The Royal Society of Chemistry 2011
Fig. 1 Determinants of safety and efficacy of herbal food supplements.
D
ow
nl
oa
de
d 
on
 0
3 
Ju
ly
 2
01
2
Pu
bl
ish
ed
 o
n 
17
 A
ug
us
t 2
01
1 
on
 h
ttp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C1
FO
101
12A
View Onlinewhile others may exert a number of undesirable effects, or none.
Many botanical constituents are actually toxins synthesized by
the plant in order to ward off predators and parasites; and some
botanical chemical compounds may act in exact opposition to
the principal active ingredient.
Botanical food supplements may be derived from secondary
food sources (e.g., soy extracts containing isoflavones, tomato
extracts rich in lycopene) or derived directly from herbs and
spices (e.g. garlic oil, rosemary extracts, green tea extracts). The
nature (species, part of the plant used), their preparation and
conditions of use (length of time, periodicity of use) determine
their impact on safety. For example, some PFS may be intended
to be used only for short periods, e.g. for weight control or
stimulation of the immune system in winter,8 andmay be harmful
if used longer.
The growing conditions (adherence to good agricultural
practice, limitation of pesticide usage) and storage conditions
(humidity, temperature) are also important as safety criteria. In
complex combinations of PFS, herbs may interact with each
other, or with other drugs or nutrients. Herbal supplements can,
like drugs, cause medical problems if not used correctly or if
taken in large amounts. Even then, some consumers can expe-
rience negative effects even when they follow the instructions on
the PFS label. Allergic reactions may occur, which are hard to
predict because they are idiosyncratic.
Other factors to be taken into account are the part of the plant
used for preparation (root, leaves, flower, fruits), the details of
extraction procedures (boiling water, lipophilic solvents, the
length of time of extraction) and type of final product (pill,
capsule, tablet, or liquid). The content and nature of biologically
active compounds of PFS may be quite different if these factors
are changed. A product may also contain, as contaminants, parts
of other herbs not mentioned on the label, which may not
accurately reflect the herbal content of the product. Microbiota
have been identified in syrups or infusions made from dried plant
blends.10
It is not possible to give a simple checklist of tests that will be
appropriate for establishing the safety of botanical food
supplements. Some authors have proposed a decision tree as an
aid to safety evaluation.8
Crucial to a successful strategy for assessing quality is the
isolation of purified reference standards of active ingredients,
botanical adulterants and contaminants, and the standardization
of accessible analytical techniques for specific identification.
Fingerprints of plant extracts (using HPLC or LC-MS) are also
recommended. These techniques provide both qualitative and
quantitative information concerning primary active compounds,
their secondary metabolites and indications of purity of the
original source material. Unexpected peaks may indicate
contamination or adulteration.9
However, the safety of botanical preparations should
primarily be assessed on the grounds of toxicity and the effect on
consumers of prolonged exposure.11Fig. 1 shows determinants of
herbal food supplements as well as the assessment of efficacy.10,12
There have been few randomized controlled studies of adverse
effects of most of the herbal ingredients currently available, so
clinicians are left to rely on case reports, passive surveillance, and
small clinical trials if they are to give advice on the safe use of
PFS.13This journal is ª The Royal Society of Chemistry 2011Due to the increasing pollution of air, water, soil, the herbal
products may be contaminated; as a consequence their compo-
sition, quality and safety must be controlled.14,153 Correct identification of plant source
The production of safe botanical food supplements of high
quality begins with plants of the correct species. Plants intended
for use in food supplements should be cultivated and harvested
using good agricultural practices, and field-collected material
should be acquired using good collection practices. The WHO
Programme on Traditional Medicines has published guidelines
for good agriculture and collection practice in the acquisition of
quality botanicals.16 If wild plant specimens are collected or if the
plant material or extracts are purchased from suppliers without
assurance of good agricultural practice, they should be assayed
more carefully.
First, the considered plant should be completely and accu-
rately identified, as follows:15,17
– scientific name (plant family, genus, species with name of
authority, and if relevant, variety, and chemotype);
– common name;
– part(s) of the plant used; and
– geographic origin.
Secondly, each batch of plants used in the production should
be identified using taxonomic examination (macroscopic and/or
microscopic) and/or a biochemical or chemical test. The several
established methods for authentication, standardization, and
quality assurance include plant taxonomic identification,
morphological and microscopic examination, fingerprint chro-
matography, DNA molecular marker characterization, and
immunoassay of species-specific proteins.12,18,19
Macroscopic identification is best done on the intact whole
plant during collection or harvesting, when the appearance,
characteristic smell or stinging properties can be examined and
the presence of contaminants, such as sand, gravel or morpho-
logically distinct plant material noted.20–26 However, macro-
scopic examination may not be sufficient to identify the species or
distinguish subtle sub-species differences in chemotype or
ecotype.
Examination under the microscope, on the other hand, can
assess whole, fragmented, or powdered plant material, including
characteristic hairs (e.g. glandular or stellate), cell types, fibres
and granular objects (e.g. starch grain, calcium oxalate crystals),
as well as minute floral and fruit characteristics. MicroscopicFood Funct., 2011, 2, 740–746 | 741
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View Onlinecharacteristics of the most important plants have been described,
but today professional microscopists trained in the analysis of
botanical materials are rare, and published reference standards
are not easy to access.27–29
‘Fingerprinting’ uses chromatographic and/or spectroscopic
profiling: high performance liquid chromatography (HPLC),
thin layer chromatography (TLC), high performance TLC
(HPTLC), or gas chromatography (GC), or Fourier transform
infrared (FTIR), near infrared (NIR), or nuclear magnetic
resonance (NMR) spectrometry. ‘Chemical fingerprinting’ takes
a group of chemicals, which are known to be present in and also
absent from a particular plant and compares its profile with that
of an extract from the plant (a) to identify and classify the plant
or material, (b) to check the quality of material or product, or (c)
to assess its purity and identify the adulterants; it may even
quantify them.30
DNA fingerprinting has recently been strongly advocated: the
genetic composition of each species is unique and is not affected
by age, physiological conditions or environmental factors. DNA
can be extracted from fresh or dried organic tissue. Molecular
genetic tools, like barcoding, random amplified polymorphic
DNA (RAPD) and sequence characterized amplified region
(SCAR) markers are reliable in quality control of products.
RAPD can be used to identify plant raw material but it is difficult
to reproduce the fingerprints and they are better converted to
SCAR markers. The limitations mean that DNA analysis has so
far been confined to academia. Furthermore, with regard to PFS
production, it is important to realise that the DNA fingerprint is
the same in every part of the plant, but the phytochemical
content is not, and this content also depends on the growing
conditions and the environment of the plant in general.31,32
4 Quality control of adulterants and naturally
occurring contaminants of concern
Among the large number of plant species marketed as health
related products in the EU, few are cultivated on a large scale,
but they account for 80% of the volume. Most commercialized
herbs are gathered from the wild, but the resultant products
constitute only 20% of the volume. Thus, in controlling the
quality of botanical raw materials consideration should of course
be given to the conditions of (controlled) cultivation, but even
more attention should be paid to the less controllable conditions
of wild collection besides the habitat, country of origin, storage
and transport.
The most important contaminants of herbal raw materials are
pesticides, heavy metals, mycotoxins and microbiological
contaminants, such as bacteria, moulds or yeasts. Recently, other
groups of substances have been recognised as important: poly-
aromatic hydrocarbons (PAH). For some of these contaminants
regulations are in place, limiting their content to technically
achievable and toxicologically acceptable levels. Most contami-
nants are present in herbal raw materials only in mg kg1 to mg
kg1 concentrations and dried herbal materials present a very
challenging matrix, so that the most advanced analytical tech-
nology is needed to quantify them reliably. In addition, toxic
substances may originate from different parts of the plant in
question or from other species. Adequate and effective control of
both contaminants and toxic plant substances requires adequate742 | Food Funct., 2011, 2, 740–746sampling schemes, and in the case of spot contaminants (e.g.,
mycotoxins and micro-organisms), extensive sampling schemes.
4.1 Pesticides
Regulation (EC) 396/2005 establishes a regime for setting and
controlling maximum residue levels (MRLs) of pesticides in food
and feedstuffs.3 In Annex I of the regulation, food is divided into
categories. There is no specific category for herbal food supple-
ments, but herbal raw materials may be assigned to one of the
categories ‘‘Vegetables, fresh or frozen’’, ‘‘Tea, Coffee, Cocoa,
Herbal Infusions’’ or ‘‘Spices’’, as appropriate, see Regulation
(EC) 178/2006.33 Provisional harmonised MRLs for known
active substances are promulgated in Annex III to the regulation
on the basis of information about national MRLs submitted by
member states. Assessments of the European Food Safety
Authority (EFSA) will form the basis of proposals to change
MRLs. A default MRL of 0.01 mg kg1 applies to products for
which no specific MRL has been set.34,35
Analytical procedures used for pesticide analysis must be
validated according to SANCO/10232/2006.36 In particular, they
must satisfy the following criteria:
– the method is suitable for the pesticide residue/substance to
be analysed and not susceptible to interference from co-
extractives;
– natural occurrence of some constituents is considered in the
interpretation of results;
– 70–110% of each pesticide should be recovered.
For routine pesticide analysis the standard methods EN
1239337 and EN 12396-338 may be used, which are commonly
established in laboratories specialized in contaminant analyses.
In assigning MRLs to specific herbs, until there are more than
a few herb-specific MRLs in Annexes II and III, the allocation
list of the European Herbal Infusions Association (EHIA) will
provide a valuable tool.39
4.2 Heavy metals
Toxic metals found in herbal raw materials include lead (Pb),
cadmium (Cd), mercury (Hg) and arsenic (As). Regulation (EC)
No. 629/200840 sets maximum levels in the EU for Pb, Cd and Hg
in food supplements. For most commercialized herbs these
maximum levels can be observed. Higher levels may exception-
ally be acceptable provided that product safety is assured.41,42
Suitable measurement methods in herbal raw materials are
provided in the European Pharmacopoeia:43 atomic absorption
spectroscopy (AAS) and inductively coupled plasma (ICP)
techniques are the methods of choice in the herbal industry.14
4.3 Mycotoxins
Mycotoxins are chemically diverse compounds produced by
moulds.Mould spores are present in all natural environments, but
their germination and growth require highly specific conditions of
humidity, light and temperature. Significant mould counts or
elevated levels of mycotoxins in a product or plant source indicate
inappropriate post-harvesting conditions either in drying, trans-
port or storage processes. Since moulds and mycotoxins typically
occur in isolated locations, reliable detection requires extensive
sampling. For dried herbs and spices no commonly agreed orThis journal is ª The Royal Society of Chemistry 2011
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View Onlineofficial sampling scheme is available. Those established for
peanuts, cereals or cocoa beans may provide an approach.
The most commonly found mycotoxins are the aflatoxins,
which may be found in a variety of foods and herbal raw mate-
rials. Other mycotoxins like patulin are restricted to certain types
of commodities: patulin is typical for apples and other fruits but
is rarely found in leafy herbs. In the EU, fourteen mycotoxins
have been accorded specific maximum levels in food, but only in
a few herbal raw materials, namely ginger (Zingiber officinale),
curcuma (Curcuma petiolata), licorice (Glycyrrhiza glabra) and
capsicum species.4,44 There is no official method for the reliable
quantification of all 14 EU-regulated mycotoxins, but the
European Pharmacopoeia provides validated methods for afla-
toxins B1, B2, G1, G2 and for ochratoxin A, which are widely
used in the herbal industry.45,46
It remains the responsibility of the food operator to assess
whether to test specific herbs for mycotoxins and, if found,
whether the detected levels might represent a health risk to
consumers in general, infants, pregnant women, or people with
kidney or liver insufficiency. SCF and EFSA Scientific Opinions
on the toxicological assessment of various mycotoxins provide
helpful guidance.
For patulin and the fusarium toxins fumonosin B1, B2, zear-
alenone and deoxynivalenol, official EN methods are available,
mostly for application to cereals or corn products. However, the
basic approach, i.e., using standardized sample preparation,
chromatographic conditions and detection method, has also
been shown to be suitable for herbal raw materials, with any
necessary adaptations for the specific matrix. Many methods to
measure fusarium toxins have been published. Taken together,
published methods allow adequate analytical control of the
mycotoxins regulated for food content in the EU.
The absolute amount of herbal material or herbal preparations
consumed in food supplements is usually small and poses only
low risk. However, the spot-contaminant nature of mycotoxins
needs to be taken into account in monitoring herbal sources.4.4 Micro-organisms
Any plant growing in a natural environment is colonized with
micro-organisms, including bacteria, microalgae, yeasts and
moulds, so that micro-organisms detected on herbal raw
materials are not necessarily contaminants in the strictest sense.
The natural opportunistic microflora found on herbal raw
materials does not normally contain pathogenic species.
However, infestation of herbal raw materials or preparations
with pathogenic species (e.g., Enterobacteriae, Salmonellae, E.
coli) or potentially pathogenic levels of opportunistic species (e.
g., Bacillus spec.) may occur during any of the post-harvesting
stages, and microbiological quality needs to be assessed
routinely in both herbal raw materials and preparations. At
present, no legal limits have been set for herbal food supple-
ments, or for that matter, the majority of food items. Because
herbal food supplements and herbal medicines are similar with
respect to raw materials, preparation and finished forms, the
European Pharmacopoeia analytical methodology is fully
applicable. The microbial limits specified in the European
Pharmacopoeia47 are equally appropriate for herbal food
supplements and their attainment has been shown to be feasibleThis journal is ª The Royal Society of Chemistry 2011provided suitable germ-reducing processing steps are applied,
e.g. water vapour treatment.4.5 Other contaminants
Polyaromatic hydrocarbons (PAH). PAH are defined as con-
taining two or more fused aromatic rings. They result from
incomplete combustion or pyrolysis of organic matter in certain
industrial processes. Food can be contaminated with PAH from
industrial food processing (smoking of meat or fish), home
cooking practices (barbecueing) or environmental sources
(mainly combustion processes). Several PAH have been shown to
be genotoxic rodent carcinogens48 and have been classified by
IARC as probable human carcinogens (class IIa). Levels of PAH
in food should therefore be kept as low as reasonably achievable.
On the basis of extensive data collection in EU countries on
PAH levels comprising ca. 10 000 samples of different food items48
and an EFSA scientific opinion regarding polycyclic hydrocar-
bons in food,49 theEuropeanCommission has recently filed a draft
regulation to set maximum levels for PAH in certain foods.50
Regulation (EC)1881/20064 on PAH levels in certain foodstuffs
is based exclusively on benzo(a)pyrene (BaP) levels, but EFSA’s
scientific opinion of 200848,49 concludes that benzo(a)pyrene
should not be used as the sole indicator of PAH contamination.
Instead, a group of four PAHs – (benzo(a)pyrene, benzo(a)
anthracene, chrysene, benzo(b)fluoranthene) – has been proposed
as a more reliable basis for assessing PAHs in food. Very few data
are available on the occurrence of PAHs in herbal ingredients used
in food supplements. On the basis of preliminary data from single
member states, draft Commission Regulation SANCO/10616/
2009 rev. 6 (28.3.2011)50 states that ‘‘High levels of PAH have been
found in some food supplements.Nevertheless, the levels are variable
and depend on the specific type of food supplements. Further data on
food supplements are needed and should be collected. Once these
data become available, the need for settingmaximum levels forPAH
in food supplements will be evaluated.’’
While legal limits for PAHs in food supplements do not
currently exist in the EU, food operators should assess the
necessity of PAH testing on a case-by-case basis considering, e.g.,
geographic origin, processing (e.g., roasting) or concentration
procedures if they involve lipophilic solvents.
Dioxins, PCBs. Maximum levels for dioxins and PCBs are
described in Regulation (EC)1881/20064 for certain foods of
animal origin, vegetable oils and fat and marine oils. Currently
there is no evidence that dioxins and PCBs are a matter of
concern for herbal food supplements.
Acrylamide. Primarily detected in fried potatoes, chips or
certain bakery products, the presence of acrylamide in herbal
preparations seems a minor problem since processes at high
temperatures (e.g., roasting) are rarely applied to them.5 Toxic plant compounds
Among contaminants, one must consider toxic substances
naturally occurring in plant sources: compounds of the herbal
raw material itself, coming from the use of the wrong parts of the
same plant or from different plant species. Official methodsFood Funct., 2011, 2, 740–746 | 743
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View Onlinedescribed in pharmacopoieas cover the most typical examples of
this type of adulteration. Because plant sourcing practices are
rapidly changing, the likeliness of intentional or unintentional
adulteration has strongly increased in recent years. This
consideration remains a major responsibility of food operators.
The amount of undesirable compounds present in the recom-
mended daily intake of a given product may be affected by the
choice of raw material, the mode of preparation (extraction
solvent, extraction temperature and duration) and by the rec-
ommended dose and conditions of use. At any stage in the process
from field to finished product, reliable analytical methods are
needed to ensure adequate quality and safety. it should be borne in
mind that different methods can produce widely different values.
The substances that need to be measured may be divided into
four groups.
First, the physiologically active substances providing the
desired effects. In some cases, the compounds may exert adverse
effects at high intake levels or in certain target populations, and
upper limits may be appropriate.
Secondly, components of the same herb that are not related to
the desired action but may cause adverse effects. This is the
largest group, since it comprises any substance contained in the
respective herb/preparation other than physiologically active
ones. Toxicological effects and dose/toxicity relations have been
established for some of the substances, which allows reasonable
limits to be derived.
Thirdly, toxic compounds resulting from confusion or adul-
terationwith other herbs or unwanted parts of the same herb. This
group is becoming increasingly important for several reasons: the
sourcing and trade of herbs and herbal preparations has become
more international with an increasingly diversified structure of
trade relations; the number of herbs/preparations traded inter-
nationally has steeply increased, creating more potential for
unintentionalmix-up; and the increasing global demand and price
level of certain herbs encourages wilful adulteration with surro-
gate plant material, including potentially toxic species.
Fourth, increased knowledge and understanding of the
phytochemical composition of herbs and herbal preparations has
created new possibilities of targeted phytochemically designed
adulteration, especially for enriched herbal extracts with a spec-
ified content of active compounds, e.g., Ginkgo biloba (flavo-
noids), Panax ginseng (ginsenosides) or Oxycoccus palustris/
cranberry (proanthocyanidins).51–53 For more details see below
(Identification of intentional adulteration).
Despite the large number of potentially occurring contami-
nants, there is no call for hysteria or for herbal products in
particular to be suspected of being at risk of contamination or
adulteration. However, examples like ochratoxin A in liquorice
show that certain herbal materials may be seriously affected by
particular contaminants.
It remains the duty of food operators to follow the scientific
literature and market information and adapt the scope of spec-
ifications, sampling schemes and methods to a fast-changing
environment and state of knowledge.6 Intentional adulteration
Adulterants may be intentionally added to products containing
botanical ingredients to increase the product bulk, to reduce744 | Food Funct., 2011, 2, 740–746manufacturing costs or for some other deceptive or illegal
purpose.54 The added substance is usually not included in the
labelling, which is not sufficiently strictly controlled.55
Several undeclared active ingredients in products marketed as
dietary supplements have been found, including anticoagulants
(e.g., warfarin), anticonvulsants (e.g., phenytoin), HMG-CoA
reductase inhibitors (e.g., lovastatin), phosphodiesterase type 5
inhibitors (e.g., sildenafil), nonsteroidal anti-inflammatory drugs
(NSAIDs; e.g., indomethacin), and beta blockers (e.g.,
propranolol). A report on Chinese herbal medicines indicated
that among 260 ‘Asian’ (no further details provided) patent
medicines collected from Californian outlets, 7% contained
undeclared pharmaceuticals.56
A systematic review briefly summarized the evidence for the
adulteration of Chinese herbal medicines by synthetic thera-
peutic substances.57 One fatality and at least six potentially life-
threatening events were presented. Phenylbutazone, phenytoin,
glibenclamide and corticosteroids were some of the adulterants
associated with serious adverse events. The concerns were
heightened by the ready availability of these products through
shops and therapists as well as by mail order and over the
Internet.
Among the adulterant substances, those promoting weight
loss, body-building, and sexual performance enhancement are
the most frequently detected.
The use of performance-enhancing drugs in sport (so-called
doping) is common, even though the practice is considered
unethical by most international sports organizations and espe-
cially the International Olympic Committee, and it can be seri-
ously detrimental to health. Anabolic steroids affect
cardiovascular and mental health and are associated with an
increased risk of cancer.57–59 Dietary supplements containing
ephedra alkaloids have been linked to hypertension, tachycardia,
stroke, seizures and death.60 The peptide hormones, so-called
‘‘sports-designer drugs’’, are thought to be the most dangerous,
while the combination of amphetamines, anabolic steroids or
antihypertensives with intense physical activity has been shown
to be responsible for severe adverse effects.
Ephedra alkaloids have produced health problems not only in
athletes but also in subjects who took Ephedra-based food
supplements in order to lose weight. A fatal case in a young,
apparently healthy male college student drew attention to the
dangers associated with ephedrine-containing products. The
student regularly consumed a product containing ephedrine and
caffeine known as Ripped Fuel. The official autopsy report and
death certificate recorded ‘‘patchy myocardial necrosis associ-
ated with ephedrine toxicity from protein drink containing ma
huang extract.’’ The blood and urine ephedrine levels suggested
that the death was not caused by acute poisoning but was the
result of chronic consumption.61,62
Because ofwidespread reports of adverse events associatedwith
ephedrine use, FDA and European Countries banned Ephedra
derivatives from the food supplements formulated for sports.6.1 Detection and quantification of added drugs
Toxicological analysis aims at controlling prohibited substances
and sometimes may be limited to qualitative analysis; however, it
is often necessary to quantify the active substances in order toThis journal is ª The Royal Society of Chemistry 2011
Fig. 2 HPTLC (left) and HPLC chromatograms (right) of standard
sibutramine and rimonabant and food supplements (modified from
Kanan et al.63).RC ¼ Red Capsule; CC ¼ Creamy Capsule; PC ¼ Phy-
toslim Capsule; Rm ¼ Rimonabant; Sb ¼ Sibutramine.
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View Onlineassess the significance of the adulteration for human health.
Reliable risk assessment requires the development and/or appli-
cation of an efficient analytical method. The analyst must select
the most appropriate method of analysis among those available.
When adulteration is suspected, the first objective is the
identification of the class of molecules to be searched for. The
chemical nature, as well as the toxicokinetic and toxicodynamic
aspects of the hypothesized agent, must be assessed, since all
these factors affect the analytical procedure, and the laboratory
involved must be suitably equipped and staffed by trained
personnel to allow rapid and valid analyses.
Several analytical approaches have been developed. Screening
is an essential first step, and more than one screening method
must be applied because thousands of chemical substances are
involved. The putative adulterant should be classified according
to its acidic, neutral or alkaline nature and separated with
appropriate solvent systems and reagents. Thin-layer chroma-
tography (TLC) and its improved version High Performance
TLC (HPTLC) are widely used in screening to detect or exclude
whole classes of substances, and is particularly suitable in
screening for hormones.
More sensitive and specific analytical techniques must be
used to quantify the contaminant, e.g. gas chromatography–
mass spectrometry (GC-MS), high-performance liquid chro-
matography (HPLC) plus mass spectrometry (HPLC-MS)
using different ion sources and analyzers, and capillary elec-
trophoresis (CE).
Knowledge of symptoms can limit the search to a few classes of
compounds, and clinical data and pharmacological activity are
available for some common food supplements, but even when
sophisticated analytical techniques are used, the identification
and quantification of adulterants requires time, expensive
procedures and the availability of purified standards.
Example 1. Kanan and co-workers reported a procedure to
detect weight-reducing ingredients in five herbal medicines.63 The
study showed that three of them had been contaminated with
synthetic rimonabant or sibutramine. The drugs were extracted
with methanol from herbal products and identified by HPLC and
HPTLC methods. The creamy and red capsule chromatograms
showed a peak at 4.76 min due to rimonabant, quantified using
the calibration curve as 18.47 and 21.40 g kg1 in the two
samples. The Phytoslim capsule showed a single peak at 2.02
min, identified as sibutramine. Quantitative analysis showed
a content of 55.20 g kg1 of sibutramine (Fig. 2 right).
Fig. 2 (left) shows the same samples analysed by HPTLC. Two
samples (Red Capsule and Creamy Capsule) had Rf values
perfectly matching those of purified rimonabant (Rm), while
Phytoslim Capsule showed a component with an Rf value similar
to that of standard sibutramin (Sb). Thus, the results obtained by
HPTLC agreed well with those obtained by HPLC.63
The herbal products had therefore been laced with synthetic
weight-loss promoters. Rimonabant and sibutramine are
prescribed for use in low dose and for a short time. Their
inclusion in food supplements constitutes a severe danger for
consumers who could easily exceed the safe dosage.
Example 2. In another study conducted by Vaysse and co-
workers, twenty herbal medicines or dietary supplementsThis journal is ª The Royal Society of Chemistry 2011marketed as natural slimming products were analysed by diffu-
sion ordered spectroscopy (DOSY), 1H-nuclear magnetic reso-
nance (NMR) and DOSY–COSY 1H-NMR.64 Of the twenty,
fourteen had been adulterated: eight contained sibutramine
alone, five contained sibutramine plus phenolphthalein, and one
contained synephrine. The substances were quantified with 1H-
NMR, and DOSY NMR was considered a useful tool for the
detection of unexpected adulteration.
Example 3. Analysis by HPLC–MS of the herbal supplement
named 28 Pc showed the presence of nimesulide, which was
responsible for reports sent to pharmacovigilance and phytovi-
gilance authorities of its ‘‘unusual’’ effectiveness in the treatment
of headache and menstrual pain.65 The product was removed
from the Italian market in response to the reports.7 Conclusions
The quality control of plant materials is critical whether
a botanical product is to be used as a medical treatment or as
a plant food supplement. For the ultimate protections of the
consumers, quality control should be applied throughout the
various processing stages, from the raw material to the finished
product. Unfortunately, there is no single or superior method to
assure 100% quality control of a product. Instead it takes
a mixture of techniques used in the correct manner, and applied
to the proper tissue, to achieve this goal.Acknowledgements
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